Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
Patients with multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) will be mobilized with
chemotherapy and G-CSF plus plerixafor (AMD3100). The purpose of this protocol is to
determine if plerixafor given after chemotherapy and G-CSF mobilization regimen is safe, if
it can increase the circulating levels of peripheral blood stem cells (PBSCs) by ≥ 2-fold
before apheresis, and if transplantation with the apheresis product was successful, as
measured by time to engraftment of polymorphonuclear leukocytes (PMNs) and platelets (PLTs).